SCHEMBL2950889

SCHEMBL2950889

Fc1ccc(CNc2ccc3ncc(-c4ccc5[nH]ccc5c4)n3n2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 7/20 0.68
PIM1 P11309 3/20 0.66
CCNT1 O60563 5/20 0.59
CDK9 P50750 5/20 0.59
CDK5 Q00535 5/20 0.59
CDK5R1 Q15078 5/20 0.59
DYRK3 O43781 4/20 0.59
DYRK1A Q13627 4/20 0.59
DYRK2 Q92630 4/20 0.59
DYRK1B Q9Y463 4/20 0.59
CCNA2 P20248 4/20 0.59
CDK2 P24941 4/20 0.59
NTRK1 P04629 5/20 0.56
NTRK3 Q16288 5/20 0.56
NTRK2 Q16620 5/20 0.56
MKNK1 Q9BUB5 2/20 0.52
ABL1 P00519 2/20 0.51
JAK2 O60674 1/20 0.51
INSR P06213 1/20 0.51
LCK P06239 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943171 0.88 FYN (0.68) FYNPIM1CCNT1CDK9CDK5
SCHEMBL2948817 0.87 FYN (0.66) FYNCCNT1CDK9CDK5CDK5R1
SCHEMBL2943211 0.86 FYN (0.62) FYNPIM1CCNT1CDK9CDK5
SCHEMBL16010383 0.83 FYN (0.88) FYNPIM1CCNT1CDK9CDK5
SCHEMBL13234623 0.82 FYN (0.79) FYNPIM1CCNT1CDK9CDK5
SCHEMBL13234428 0.82 FYN (0.67) FYNPIM1CCNT1CDK9CDK5
SCHEMBL2255614 0.81 FYN (0.60) FYNPIM1CCNT1CDK9CDK5
SCHEMBL1202861 0.81 NPC1 (0.50) FYNPIM1CCNT1CDK9CDK5
SCHEMBL1202385 0.81 FYN (0.47) FYNPIM1CCNT1CDK9CDK5
SCHEMBL2949403 0.81 FYN (1.00) FYNPIM1CCNT1CDK9CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
WO-2007025540-A2 SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885PIM1 365/4885CCNT1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.